Bollard Group’s AbbVie ABBV Stock Holding History

Bollard Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$559K	Buy	2,222 +27	+1%	+$5.81K	0.02%	128
2026 Q1	$477K	Buy	2,195 +16	+0.7%	+$3.55K	0.01%	140
2025 Q4	$498K	Buy	2,179 +1	+0%	+$228	0.01%	131
2025 Q3	$504K	Buy	2,178 +1	+0%	+$204	0.01%	136
2025 Q2	$404K	Buy	2,177 +102	+5%	+$19K	0.01%	159
2025 Q1	$435K	Buy	2,075 +1	+0%	+$194	0.01%	140
2024 Q4	$369K	Sell	2,074 -188	-8%	-$34.6K	0.01%	143
2024 Q3	$447K	Buy	2,262 +2	+0.1%	+$373	0.01%	151
2024 Q2	$388K	Sell	2,260 -1,363	-38%	-$226K	0.01%	149
2024 Q1	$660K	Sell	3,623 -243	-6%	-$41.9K	0.02%	125
2023 Q4	$599K	Sell	3,866 -722	-16%	-$105K	0.02%	122
2023 Q3	$684K	Buy	4,588 +25	+0.5%	+$3.67K	0.03%	116
2023 Q2	$615K	Buy	4,563 +151	+3%	+$22.1K	0.02%	126
2023 Q1	$703K	Buy	4,412 +23	+0.5%	+$3.52K	0.03%	120
2022 Q4	$709K	Buy	4,389 +23	+0.5%	+$3.53K	0.03%	115
2022 Q3	$586K	Buy	4,366 +24	+0.6%	+$3.44K	0.02%	122
2022 Q2	$665K	Buy	4,342 +22	+0.5%	+$3.36K	0.03%	129
2022 Q1	$700K	Buy	4,320 +24	+0.6%	+$3.49K	0.02%	157
2021 Q4	$582K	Buy	4,296 +26	+0.6%	+$3.07K	0.02%	161
2021 Q3	$461K	Buy	4,270 +26	+0.6%	+$2.97K	0.02%	173
2021 Q2	$478K	Buy	4,244 +25	+0.6%	+$2.82K	0.02%	163
2021 Q1	$457K	Buy	4,219 +28	+0.7%	+$3K	0.02%	161
2020 Q4	$449K	Buy	4,191 +27	+0.6%	+$2.6K	0.02%	152
2020 Q3	$365K	Buy	4,164 +28	+0.7%	+$2.64K	0.01%	161
2020 Q2	$406K	Buy	4,136 +28	+0.7%	+$2.46K	0.02%	148
2020 Q1	$313K	Buy	4,108 +26	+0.6%	+$2.21K	0.01%	134
2019 Q4	$361K	Buy	4,082 +27	+0.7%	+$2.24K	0.01%	141
2019 Q3	$307K	Buy	4,055 +34	+0.8%	+$2.33K	0.01%	146
2019 Q2	$292K	Buy	4,021 +28	+0.7%	+$2.2K	0.01%	163
2019 Q1	$322K	Buy	3,993 +27	+0.7%	+$2.21K	0.01%	157
2018 Q4	$366K	Buy	3,966 +121	+3%	+$10.6K	0.02%	150
2018 Q3	$364K	Buy	3,845 +20	+0.5%	+$1.9K	0.01%	153
2018 Q2	$354K	Buy	3,825 +18	+0.5%	+$1.76K	0.02%	153
2018 Q1	$360K	Buy	3,807 +13	+0.3%	+$1.43K	0.02%	154
2017 Q4	$367K	Buy	3,794 +13	+0.3%	+$1.23K	0.02%	149
2017 Q3	$336K	Buy	3,781 +17	+0.5%	+$1.29K	0.02%	156
2017 Q2	$273K	Buy	3,764 +19	+0.5%	+$1.28K	0.01%	171
2017 Q1	$244K	Buy	3,745 +20	+0.5%	+$1.26K	0.01%	176
2016 Q4	$233K	Buy	3,725 +16	+0.4%	+$977	0.02%	178
2016 Q3	$234K	Buy	3,709 +16	+0.4%	+$1.04K	0.02%	176
2016 Q2	$229K	Buy	3,693 +17	+0.5%	+$1.04K	0.02%	183
2016 Q1	$210K	Buy	3,676 +19	+0.5%	+$1.06K	0.02%	179
2015 Q4	$217K	Buy	3,657 +15	+0.4%	+$864	0.02%	180
2015 Q3	$198K	Buy	3,642 +1,813	+99%	+$118K	0.02%	197
2015 Q2	$123K	Buy	1,829 +14	+0.8%	+$914	0.01%	206
2015 Q1	$106K	Buy	1,815 +15	+0.8%	+$906	0.01%	209
2014 Q4	$118K	Hold	1,800	–	–	0.01%	197
2014 Q3	$104K	Hold	1,800	–	–	0.01%	215
2014 Q2	$102K	Hold	1,800	–	–	0.01%	212
2014 Q1	$93K	Hold	1,800	–	–	0.01%	211
2013 Q4	$95K	Hold	1,800	–	–	0.01%	205
2013 Q3	$81K	Buy	+1,800	New	+$79.8K	0.01%	212

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bollard Group's ABBV Position: Q2 2026 in Review

Bollard Group increased its AbbVie (ABBV) stake by 1.2% in Q2 2026, buying an estimated $5.81K and bringing the position to 2,222 shares worth $559K. The position accounts for 0.02% of the portfolio, ranked #128.

Bollard Group first reported a position in ABBV in Q3 2013 and has held it in 52 quarters since. The position peaked at $709K in Q4 2022. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Bollard Group held 2,222 shares of AbbVie worth $559K as of Q2 2026.
Bollard Group bought 27 AbbVie shares in Q2 2026, an estimated $5.81K.
AbbVie made up 0.02% of Bollard Group's portfolio in Q2 2026, its #128 holding.
Bollard Group first reported a position in AbbVie in Q3 2013 and has held it in 52 quarters since.
Bollard Group's AbbVie position peaked at $709K in Q4 2022.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Bollard Group's 13F filing for Q2 2026, filed 12 Aug 2026.